Fri, Jul 25, 2014, 5:43 AM EDT - U.S. Markets open in 3 hrs 47 mins

Recent

% | $
Click the to save as a favorite.

Curis, Inc. Message Board

dbaaaa 4 posts  |  Last Activity: Jul 17, 2014 7:04 AM Member since: Jan 17, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Re: brownsfan407 Post# 703
    IP situation: posting my earlier reply from Cafepharma to another overly optimistic plecanatide IP spin post - enjoy.

    Quote:
    Originally Posted by Anonymous

    IP agreement with IRWD blocks competition. Despite the company’s patent–license agreement with Ironwood, there’s still some investor belief that an intellectual property overhang exists on the stock, thus, the company’s plecanatide patents are worth touching on. The patent deal with IRWD, announced in September of 2012, actually blocks other companies from entering into the GC-C agonist segment and competing in the key IBS-C or CIC indications, or any other inflammatory GI diseases or cancers with the technology. As a result, for large companies hoping to enter this drug class, SGYP is the only asset available for acquisition or partnering and this is why the company is likely to be on analyst take-out lists this year. Synergy has two patents covering the composition of plecanatide – one is a broad patent covering several analogues of uroquanylin (the parent structure of plecanatide), and the other is a patent covering the specific structure of plecanatide itself. These patents, with Hatch Waxman exclusivity, are expected to expire in 2025, and the company continues to evolve its patent estate.

    Plecanatide is an analogue of uroquanylin, with one amino acid different from the active form of uroquanylin. The replacement of aspartic acid with glutamic acid fixes the structure in a rigid (partially closed) state, which was designed to act in the intestine and is more stable and more potent than uroquanylin. This novel peptide structure was also designed for optimum low-cost manufacturing.
    Ironwood obtained a patent on the use of plecanatide in IBS-C and CIC after multiple rejections by the U.S. Patent and Trade Office (PTO), but of course, Ironwood cannot sell the product in these indications because plecanatide (its composition of matter) is owned by Synergy. Synergy never applied

  • dbaaaa by dbaaaa May 20, 2014 10:02 AM Flag

    Back in the driver's seat

CRIS
1.79+0.01(+0.56%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.